Lasa Supergenerics Limited
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.
What Lasa files
- Others40
- Board Meeting18
- Important15
- Updates5
- Results5
LASA Supergenerics' financial results received a Qualified Opinion from auditors. Unassessed damage from a May 2025 factory fire (uninsured assets) and impairment of Rs 16.67 Cr intangible assets are key concerns. Auditors rejected management's reasons for delaying these assessments. Current borrowings surged significantly.
Lasa Supergenerics' Company Secretary & Compliance Officer, Mitti Jain, has resigned. The reason cited is the company's current non-operational status and absence of active business operations, raising investor concerns about company activity.
Lasa Supergenerics Limited has announced a minor fire at its Lote Parshuram plant, causing limited damage to inventory, machinery, and office space. There were no casualties or serious injuries. The company is assessing the impact and aims to resume production within a few days. Swift management of the incident aims...
Lasa Supergenerics Limited has announced the successful expansion of its manufacturing capacity for Albendazole USP, enhancing its ability to meet the rising global demand. This initiative involved strategic debottlenecking of existing infrastructure and the installation of new machinery at their facility, anticipating a 20% growth in total capacity. This expansion,...
Lasa Supergenerics Limited has successfully resolved a significant financial challenge following the withdrawal of an insolvency application filed by Bank of Baroda under the Insolvency and Bankruptcy Code. This development comes after extensive negotiations, culminating in a settlement that focuses on the company's financial stability. The withdrawal of the application...